Breakthrough
Technology.
Transforming Drug Discovery.
Drug discovery is a long, expensive, and complex process. Our suite of groundbreaking protein footprinting technologies make for faster, more accurate, and more efficient characterization. That translates into better data, lower costs, and faster turnaround time.
The Multi-Billion Dollar Bottleneck.
Drug developers need every advantage to ensure their time, effort, and investment result in a successful, first-in-class product.
13.5 years
from discovery to development
$1.8 billion
to bring a therapeutic to market
Only 8%
of therapeutic candidates make it through candidate selection
The Solution
A New Paradigm in Drug Discovery.
Protein structural analysis is an essential step in the drug discovery process, and compared to all other methods used today, our suite of proprietary technologies enables developers to investigate interactions of therapeutics and their targets with an unprecedented degree of accuracy and speed.
That means significantly reducing uncertainty — and the costs related to it.
Novel Epitope Mapping:
Unlike other methods, our groundbreaking suite of technologies for the first time makes it possible to map epitopes and paratopes quickly, reliably through a native, in-solution analysis.
Lead Optimization.
Optimized.
We partner with pharmaceutical companies in drug discovery to streamline their lead optimization, helping to reduce cycle times, increase lead candidates, and maximize the probability of drug success leading up to clinical trials.
Quick Turnaround:
Get results in 2–3 weeks to perform rapid lead optimization iteration
Reduce Cost:
Can be performed on many lead candidates simultaneously
Native Analysis:
Native structure and protein conditions for biologically-relevant results
Faster IP Filings:
Better epitope findings earlier make for stronger claims
Protein Compatibility:
Can be used to analyze challenging protein targets
Introducing PLIMB:
Rapid High-Resolution Analysis
Our core proprietary technology, PLIMB (Plasma Induced Modification of Biomolecules) is setting a new standard for epitope mapping and structural analysis.
PLIMB provides high-resolution data on antibody binding while eliminating other costly inefficiencies, so developers can zero-in on multiple high-probability leads at the same time.
Our core proprietary technology, PLIMB (Plasma Induced Modification of Biomolecules) is setting a new standard for epitope mapping and structural analysis.
PLIMB provides high-resolution data on antibody binding while eliminating other costly inefficiencies, so developers can zero-in on multiple high-probability leads at the same time.
No lengthy protein crystallization required
Performed in biologically-relevant buffer
Requires minimal sample sizes (>5ug per sample)
High throughputs for multiple, synchronous targeting
Analyzes proteins incompatible with other techniques
Prevents denaturization through sub-microsecond timescale
The Proof Is in the Papers.
Our findings have been published in some of the most prestigious peer-reviewed journals. Your therapeutics save lives. We save you time and resources.
Plasma-Generated OH Radical Production for Analyzing 3D Structure
Effect of Frequency and Applied Voltage of An Atmospheric-Pressure
Latest News
October 9, 2021
Immuto Scientific raises $2.3 million in seed funding
Measuring the Conformational Effects of RORG Residues
In Good Company
